There are potential RNA drug targets in nearly every disease process. Small molecules offer some key potential advantages as chemical probes and lead drug molecules targeting RNA. Small molecules typically target structured regions that often play critical roles in disease biology, and their properties can be more easily optimized compared to oligonucleotides-based therapeutic agents. One of the major challenges SMIRNAs has been the perception that selectivity and potency are difficult to achieve.